Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Edesa Biotech Inc (NQ: EDSA )

4.646 +0.126 (+2.78%)
Streaming Delayed Price Updated: 2:54 PM EDT, May 17, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Edesa Biotech Inc

< Previous 1 2 3 4 5 Next >
Edesa Biotech to Participate in Upcoming Canaccord Genuity Growth Conference
Via ACCESSWIRE
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
It's time to start off the trading week with a breakdown of all the biggest pre-market stock movers worth watching on Monday! 
Via InvestorPlace
Edesa Biotech's COVID-19 Candidate Restraints Inflammation From Influenza, Other Pathogens In Preclinical Studies
Edesa Biotech Inc (NASDAQ: EDSA) released findings from an in vitro study involving its monoclonal antibody candidate, paridiprubart.  
Via Benzinga
Edesa Biotech's ARDS Drug Inhibits Inflammation from Influenza and Other Pathogens
Via ACCESSWIRE
Edesa Biotech's Dermatitis Study Data Fails To Cheer Investors
Via Benzinga
Edesa Biotech Appoints Biotech Deal Veteran to CFO Role
Via ACCESSWIRE
Edesa Biotech Reports Fiscal 2nd Quarter 2023 Results
Via ACCESSWIRE
Edesa Biotech to Participate in Swiss Biotech Day
Via ACCESSWIRE
The WHO and USAN Adopt Generic Name for Edesa's ARDS Drug Candidate
Via ACCESSWIRE
Edesa Biotech to Participate in HC Wainwright Autoimmune & Inflammatory Disease Conference
Via ACCESSWIRE
Edesa Biotech to Present Favorable Dermatitis Drug Results at American Academy of Dermatology Association Annual Meeting
Via ACCESSWIRE
Edesa Biotech and FDA Agree on Primary Endpoint for Phase 3 ARDS Drug Study
Via ACCESSWIRE
Edesa Biotech Reports Fiscal 1st Quarter 2023 Results
Via ACCESSWIRE
Edesa Biotech Receives Regulatory Approval for Phase 2 Vitiligo Study
Via ACCESSWIRE
Why Arcimoto Shares Are Trading Lower By 44%; Here Are 20 Stocks Moving Premarket
Gainers Siyata Mobile Inc. (NASDAQ: SYTA) rose 41.5% to $0.3255 in pre-market trading after gaining 8% on Tuesday. 
Via Benzinga
Nasdaq Edges Higher; Neovasc Shares Jump
U.S. stocks traded mixed toward the end of trading, with the Nasdaq Composite turning higher on Tuesday. 
Via Benzinga
Why Calyxt Shares Are Trading Higher By Around 116%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Gainers Celyad Oncology SA (NASDAQ: CYAD) jumped 187% to $2.30 after gaining 21% on Friday. Celyad Oncology, last month, decided to discontinue the development of its remaining clinical program... 
Via Benzinga
Dow Tumbles 300 Points; Morgan Stanley Beats Q4 Views
U.S. stocks traded mostly lower midway through trading, with the Dow Jones dropping over 300 points on Tuesday. 
Via Benzinga
Dow Drops Over 150 Points; Goldman Sachs Profit Misses Expectations
U.S. stocks traded lower this morning, with the Dow Jones dropping over 150 points on Tuesday. 
Via Benzinga
Edesa Biotech Reports Topline Phase 2b Results for Dermatology Drug
Via ACCESSWIRE
Why Applied Molecular Transport Shares Are Trading Lower By Over 55%? Here Are 47 Stocks Moving In Friday's Mid-Day Session
Gainers 
Via Benzinga
FDA Grants Fast Track to Edesa Biotech's ARDS Drug Candidate
Via ACCESSWIRE
Why AMC Entertainment Shares Are Trading Lower By Around 13%? Here Are 59 Stocks Moving In Thursday's Mid-Day Session
Gainers Core Scientific, Inc. (NASDAQ: CORZ) shares jumped 188% to $0.1471. Core Scientific shares dipped 75% on Wednesday after the company filed for Chapter 11 bankruptcy. 
Via Benzinga
Edesa Biotech Reports Fiscal Year 2022 Results
Via ACCESSWIRE
Edesa Biotech to Participate in the 2022 Cantor Fitzgerald Dermatology Conference
Via ACCESSWIRE
Edesa Biotech Announces Closing of $3.0 Million Private Placement Priced At-the-Market
Via ACCESSWIRE
Why F45 Training Shares Climbed 41%; Here Are 84 Biggest Movers From Friday
Gainers FingerMotion, Inc. (NASDAQ: FNGR) gained 82.2% to close at $3.37. 
Via Benzinga
What Is Going on With Edesa Biotech (EDSA) Stock Today?
Edesa Biotech released encouraging Phase 2 results for its respiratory-syndrome-targeting antibody, thus initially boosting EDSA stock. 
Via InvestorPlace
Edesa Biotech Reports Statistically Significant Mortality Reductions in Phase 2 ARDS Drug Study
Via ACCESSWIRE
Edesa Biotech to Present at Upcoming H.C. Wainwright Investor Conference
Via ACCESSWIRE
< Previous 1 2 3 4 5 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.